CD274 and neoplasm: Notably, inspired by the synergistic antitumor activity of CXCL8-CXCR1/2 and ICB in murine tumor models, clinical trials exploring combinations of these inhibitors with PD-1/PD-L1 blockade are underway.420 These combination strategies offer new avenues to enhance the efficacy of existing and emerging treatments.